Bristol-Myers inks two research pacts | Chemical & Engineering News
Volume 85 Issue 1 | p. 12 | Concentrates
Issue Date: January 1, 2007

Bristol-Myers inks two research pacts

Department: Business

Bristol-Myers Squibb will work with Exelixis to discover, develop, and market new cancer therapies. Under the deal, Exelixis will receive $60 million in cash up front and $20 million for each of up to three investigational new drug candidates selected by the drug firm. BMS has also entered a two-year drug discovery collaboration with Albany Molecular Research Inc. AMRI will test samples from its natural products library against drug targets in a range of therapeutic areas. The deal includes unspecified up-front payments, research funding, and milestone payments.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment